Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Cross

Showing results (361-370 of 382) with videos related to

Pageof 39
Sort By:
ACS Medicinal Chemistry Letters|February 18, 2026
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole CoreJoshua B Cox, Vinay Nair, Pijus Mandal, et al.
Journal of Neuroinflammation|June 24, 2026
Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in miceJacqui S Scott, Sadia Munir, Miriam A Lynn, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Nephrology (Carlton, Vic.)|January 4, 2012
KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsSteven J Chadban, Katherine A Barraclough, Scott B Campbell, et al.
Journal of the American Society of Nephrology : JASN|May 2, 2019
One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study)Germaine Wong, Richard L Hope, Kirsten Howard, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2017
Structure-based discovery of LpxC inhibitorsJing Zhang, Audrey Chan, Blaise Lippa, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
The Journal of Bone and Joint Surgery. American Volume|June 21, 2022
An Enhanced Understanding of Culture-Negative Periprosthetic Joint Infection with Next-Generation Sequencing: A Multicenter StudyKaran Goswami, Samuel Clarkson, Caleb D Phillips, et al.
Pageof 39

Showing results (361-370 of 382) with videos related to

Sort By:
Pageof 39
ACS Medicinal Chemistry Letters|February 18, 2026
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole CoreJoshua B Cox, Vinay Nair, Pijus Mandal, et al.
Journal of Neuroinflammation|June 24, 2026
Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in miceJacqui S Scott, Sadia Munir, Miriam A Lynn, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Nephrology (Carlton, Vic.)|January 4, 2012
KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsSteven J Chadban, Katherine A Barraclough, Scott B Campbell, et al.
Journal of the American Society of Nephrology : JASN|May 2, 2019
One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study)Germaine Wong, Richard L Hope, Kirsten Howard, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2017
Structure-based discovery of LpxC inhibitorsJing Zhang, Audrey Chan, Blaise Lippa, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
The Journal of Bone and Joint Surgery. American Volume|June 21, 2022
An Enhanced Understanding of Culture-Negative Periprosthetic Joint Infection with Next-Generation Sequencing: A Multicenter StudyKaran Goswami, Samuel Clarkson, Caleb D Phillips, et al.
Pageof 39